RENACET

The tablet can be divided into equal halves. Dosage should be effected individually. Unless a different dose has been prescribed, adults should take no more than 7 Renacet 950 mg film-coated tablets daily. To achieve optimal efficacy, Renacet 950 mg should be taken during or immediately after meals.

The recommended dose is: with breakfast: ½ to 1 film-coated tablet Renacet 950 mg with a snack: ½ to 1 film-coated tablet Renacet 950 mg with a main meal: 1 to 3 film-coated tablets Renacet 950 mg with supper: 1 to 2 film-coated tablets Renacet 950 mg Renacet 950 mg should be taken with some liquid during or immediately after meals and must not be chewed.

Experience with children is not available.

g. in the fatty tissue under the skin) usually occurring only after many years of intake and frequently associated with increased blood calcium levels.

Cardiac/vascular disorders:

Uncommon: Hypercalcemia, especially following overdosage.

Gastrointestinal disorders:

Rare: Gastrointestinal disorders such as nausea and constipation, especially in case of too high dosages. If gastrointestinal side effects occur, treatment should be changed to calcium carbonate as appropriate. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.

It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard

Treatment with Renacet 950 mg requires regular measurement of the serum calcium and serum phosphate levels. 3 mmol/l since the frequency of extraosseous calcification increases if this value is exceeded. To avoid an increase in serum calcium level beyond the normal range the intake of Renacet 950 mg should be monitored regularly when patients are already on preparations which contain calcium.

Patients with the rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine. Excipients Renacet 950 mg contains less than 1 mmol sodium (23 mg) per film-coated tablet, that is to say essentially “sodium-free”.

1. Hypophosphatemia, severe hypophosphatemia, hypercalcemia, hypercalciuria associated with calcium-containing kidney stones, decalcifying tumors and skeletal metastases, severe renal failure without dialysis treatment, constipation, known stenosis of the large intestine, osteoporosis due to immobilisation.